Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
- DOI
- 10.1074/jbc.m113.477216
- Published
- 2013 Jul 5
- Container
- The Journal of biological chemistry
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 39/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- cautionRetraction Watch correction: 1 correction notice matched this DOI.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1074/jbc.m113.477216,
title = {Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.},
author = {Lin TH and Lee SO and Niu Y and Xu D and Liang L and Li L and Yeh SD and Fujimoto N and Yeh S and Chang C},
year = {2013},
journal = {The Journal of biological chemistry},
doi = {10.1074/jbc.m113.477216},
url = {https://doi.org/10.1074/jbc.m113.477216}
}RIS
TY - JOUR TI - Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. AU - Lin TH AU - Lee SO AU - Niu Y AU - Xu D AU - Liang L AU - Li L AU - Yeh SD AU - Fujimoto N AU - Yeh S AU - Chang C PY - 2013 JO - The Journal of biological chemistry DO - 10.1074/jbc.m113.477216 UR - https://doi.org/10.1074/jbc.m113.477216 ER -
APA
TH, L., SO, L., Y, N., D, X., L, L., L, L., SD, Y., N, F., S, Y., & C, C. (2013). Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.. The Journal of biological chemistry. https://doi.org/10.1074/jbc.m113.477216
Source records
- pubmed · retrieved 2026-09-25T01:05:09.711Z